Skip to main content

Table 1 Baseline characteristics of 124 patients with MMN included in this study

From: IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset

 

MMN

IgM binding experiments

p

N = 124

Serum available (n = 98)

No serum available (n = 26)

Male sex$

93 (75)

76 (77)

17 (65)

0.31

Age at onset (years)#

42 (16)

41 (13)

43 (24)

0.45

Diagnostic delay (years)#

6.8 (12)

7.5 (16)

5.7 (5.3)

0.22

MMN EFNS 2010 diagnosis$

   

0.69

 Definite

88 (72)

68 (70)

20 (77)

 

 Probable

26 (21)

21 (22)

5 (19)

 

 Possible

9 (7)

8 (8)

1 (4)

 

IgM Anti-GM1 positive$

72 (58)

52 (53)

20 (77)

0.049*

IgM Anti-GM2 positive$

13 (10)

11 (11)

2 (8)

0.60

IVIg treatment at sampling$

-

85 (87)

-

 

IVIg dosage (grams/week) #

-

13

-

 
  1. A separate column shows the baseline characteristics of 98 patients with MMN of whom serum was available for SC IgM binding experiments. Comparisons were made between this group of 98 patients and the remainder of patients (n = 26), the p-values of which are shown in the right column. A separate column shows the baseline characteristics of 98 patients with MMN of whom serum was available for SC IgM binding experiments. Comparisons were made between this group of 98 patients and the remainder of patients (n = 26), the p-values of which are shown in the right column
  2. *Statistically significant at p-value < 0.05
  3. $ Values displayed as n (%)
  4. # Values displayed as median (IQR)
  5. SC Schwann cell, EFNS European federation of neurological societies, IVIg intravenous immunoglobulin, MMN Multifocal motor neuropathy
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094